FBRX · Forte Biosciences, Inc.
$76.56
-0.09 (-0.12%)
At close · Jul 29
Market Cap
$1.06B
Shares
13.89M
Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.
Fiscal 2025
| Executive | Role | Total |
|---|---|---|
| Paul Wagner | CEO | $7,358,587 |
| Antony A. Riley | CFO | $2,722,440 |
Fiscal 2024
| Executive | Role | Total |
|---|---|---|
| Paul Wagner | CEO | $1,674,458 |
| Antony A. Riley | CFO | $856,875 |
| Hubert C. Chen | Former President and Chief Scientific Officer | $230,337 |
Fiscal 2023
| Executive | Role | Total |
|---|---|---|
| Paul Wagner | CEO | $1,450,175 |
| Antony A. Riley | CFO | $722,980 |
| Hubert C. Chen | Former President and Chief Scientific Officer | $573,600 |
Fiscal 2022
| Executive | Role | Total |
|---|---|---|
| Paul Wagner | CEO | $1,227,610 |
| Antony A. Riley | CFO | $610,278 |
| Hubert C. Chen | Former President and Chief Scientific Officer | $569,857 |
Fiscal 2021
| Executive | Role | Total |
|---|---|---|
| Paul Wagner | CEO | $5,415,196 |
| Antony A. Riley | CFO | $1,766,784 |
Fiscal 2020
| Executive | Role | Total |
|---|---|---|
| Marty J. Duvall | CEO | $1,173,550 |
| Antony A. Riley | CFO | $1,056,250 |
| Paul Wagner | CEO | $776,917 |
| Mark Foletta | CFO | $689,961 |
Fiscal 2019
| Executive | Role | Total |
|---|---|---|
| Marty J. Duvall | CEO | $1,772,911 |
| Mark Foletta | CFO | $981,111 |
| Paul Wagner | CEO | $525,000 |
| Antony A. Riley | CFO | — |
Executive changes
| Person | Role | Change | Filed |
|---|---|---|---|
| Paul A. Wagner, Ph.D. | Class III director | Appointed | 2026-06-02 |
| Scott Brun, M.D. | Class III director | Appointed | 2026-06-02 |
| Steven Kornfeld | Class III director | Appointed | 2026-06-02 |